

References:

1. GAMUNEX-C (immune globulin injection [human], 10% caprylate/chromatography purified) [package insert]. Research Triangle Park, NC: Grifols Therapeutics Inc.; 2010.
2. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. *Neurology*. 2012;78(13):1009-1015.
3. Latov N. Diagnosis of CIDP. *Neurology*. 2002;59(suppl 6):S2-S6.
4. NINDS chronic inflammatory demyelinating polyneuropathy (CIDP) information page. National Institute of Neurological Disorders and Stroke website. <http://www.ninds.nih.gov/disorders/cidp/cidp.htm>. Accessed July 3, 2012.
5. Köller H, Kieseier BC, Jander S, Hartung H-P. Chronic inflammatory demyelinating polyneuropathy. *N Engl J Med*. 2005;352:1343-1356.
6. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. *Muscle Nerve*. 2009;39:432-438.
7. Hughes RAC, Donofrio P, Bril V, et al; on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. *Lancet Neurol*. 2008;7:136-144.
8. Latov N, Deng C, Dalakas MC, et al; for the IGIV-C CIDP Efficacy (ICE) Study Group. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. *Arch Neurol*. 2010;67(7):802-807.
9. Merkies ISJ, Bril V, Dalakas MC, et al; on behalf of the ICE Study Group. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE study. *Neurology*. 2009;72:1337-1344.
10. Ware JE Jr. SF-36 health survey update. *Spine*. 2000;25(24):3130-3139.
11. About PI. National Primary Immunodeficiency Resource Center website. <http://www.info4pi.org/aboutPI/index.cfm?section=aboutPI&content=warningsigns&TrkId=24&CFID=825433&CFTOKEN=94322609>. Accessed July 11, 2012.
12. Roifman CM, Schroeder H, Berger M, et al; for the IGIV-C in PID Study Group. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. *Int Immunopharmacol*. 2003;3:1325-1333.
13. Wasserman RL, Irani A-M, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. *Clin Exp Immunol*. 2010;161:518-526.
14. Bussel JB, Eldor A, Kelton JG, et al; for the IGIV-C in ITP Study Group. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. *Thromb Haemost*. 2004;91:771-778. GAMUNEX iDETAIL 9/06/12.fdfdfdfdfdfdfdfdfdfdfdfdfdfdfdfdfdf
15. Gelfand, EW. Differences between IGIV products: impact on clinical outcome. *Int Immunopharmacol*. 2006;6:592-599.
16. Data on file, Grifols Therapeutics Inc.